Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 200 Total
PACS - PACS Group Inc. - Stock Price Chart
TickerPACS [NYSE]
CompanyPACS Group Inc.
CountryUSA
IndustryMedical Care Facilities
Market Cap4.04BEPS (ttm)-
P/E-EPS this Y67.13%
Forward P/E14.68EPS next Y26.80%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B5.18EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own88.43%Inst Own-
Insider Trans-2.36%Inst Trans-
Short Float4.58%EarningsMay 13/a
Analyst Recom1.00Target Price30.67
Avg Volume846.12K52W Range22.61 - 25.72
PACS Group, Inc. is a post-acute healthcare company, primarily focuses on delivering skilled nursing care through a portfolio of independently operated facilities. It also provides senior care, assisted living, and independent living options in some communities. The company provides services under brand name is :Pacs post acute, Pacs serives, Pacs properties and Pacs ventures. PACS Group was founded by Jason Murray and Mark Hancock on January 1, 2013 and is headquartered in Farmington, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murray Jason HulseCo-Founder, CEO & ChairmanApr 15 '24Sale21.001,607,14233,749,98262,754,551Apr 15 04:02 PM
Hancock MarkCo-Founder & Exec. Vice Chair.Apr 15 '24Sale21.001,607,14233,749,98262,754,551Apr 15 04:02 PM
Millard JacquelineDirectorApr 11 '24Buy23.084339,993433May 13 05:31 PM
RNA - Avidity Biosciences Inc - Stock Price Chart
TickerRNA [NASD, RUT]
CompanyAvidity Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap2.76BEPS (ttm)-2.95
P/E-EPS this Y-8.78%
Forward P/E-EPS next Y-5.75%
PEG-EPS past 5Y-57.60%
P/S254.37EPS next 5Y-
P/B3.33EPS Q/Q-6.13%
Dividend-Sales Q/Q58.67%
Insider Own10.48%Inst Own86.34%
Insider Trans-3.51%Inst Trans-0.74%
Short Float13.30%EarningsMay 09/a
Analyst Recom1.00Target Price45.25
Avg Volume1.17M52W Range4.82 - 27.66
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyce SarahPresident and CEOMay 07 '24Option Exercise1.2428,00034,720140,117May 07 09:52 PM
Boyce SarahPresident and CEOMay 07 '24Sale25.5428,000715,050112,117May 07 09:52 PM
LEVIN ARTHUR ADirectorApr 19 '24Option Exercise1.245,0006,20019,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 19 '24Sale22.825,000114,12314,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 03 '24Sale27.1120,000542,214253,872Apr 03 08:26 PM
ERJ - Embraer S.A. ADR - Stock Price Chart
TickerERJ [NYSE]
CompanyEmbraer S.A. ADR
CountryBrazil
IndustryAerospace & Defense
Market Cap5.30BEPS (ttm)1.43
P/E20.21EPS this Y51.74%
Forward P/E14.93EPS next Y42.62%
PEG1.19EPS past 5Y-
P/S0.97EPS next 5Y17.00%
P/B1.90EPS Q/Q140.65%
Dividend0.36%Sales Q/Q25.19%
Insider Own0.05%Inst Own38.46%
Insider Trans0.00%Inst Trans0.75%
Short Float2.23%EarningsMay 07/b
Analyst Recom1.38Target Price32.05
Avg Volume1.88M52W Range12.48 - 27.47
Embraer SA engages in the design, manufacture, and sale of aircraft and its parts for commercial, defense, and executive aviation sectors. It operates through the following segments: Commercial Aviation, Defense and Security, Executive Jet Business, Service & Support and Others. The Commercial Aviation segment is involved in the development, production, and sale of commercial jets; and the provision of support services to regional aviation and aircraft leasing. The Defense and Security segment engages in research, development, production, modification, and support for defense and security aircrafts, as well as other integrated products and solutions including satellites and information and communication systems. The Executive Jet Business segment deals with the development, manufacture, and sale of executive jets. The Service & Support segment provides after-service solutions and support to its customers through a comprehensive portfolio of innovative and competitive solutions to ensure operational efficiency of products manufactured by Embraer and by other aircraft manufacturers, extending the useful life of commercial, executive and defense aircraft. The Others segment refers to the supply of structural parts and hydraulic systems and the production of agricultural sprayers. The company was founded by Ozires Silva on August 19, 1969 and is headquartered in Sao Paulo, Brazil.
VIRT - Virtu Financial Inc - Stock Price Chart
TickerVIRT [NASD]
CompanyVirtu Financial Inc
CountryUSA
IndustryCapital Markets
Market Cap2.13BEPS (ttm)1.43
P/E16.80EPS this Y36.42%
Forward P/E9.06EPS next Y5.72%
PEG-EPS past 5Y-12.55%
P/S0.97EPS next 5Y-0.60%
P/B1.77EPS Q/Q5.00%
Dividend3.99%Sales Q/Q13.95%
Insider Own5.60%Inst Own83.78%
Insider Trans1.02%Inst Trans-1.33%
Short Float1.72%EarningsApr 24/b
Analyst Recom2.00Target Price23.71
Avg Volume1.01M52W Range16.02 - 23.10
Virtu Financial, Inc. engages in the provision of trading solutions and liquidity services. It operates through the following segments: Market Making, Execution Services and Corporate. The Market Making segment involves the cash, futures, and options markets across global equities, fixed income, currencies, cryptocurrencies, and commodities. The Execution Services segment includes agency-based, execution-only trading, workflow technology, and trading analytics. The Corporate segment consists of investments in financial services-oriented opportunities and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded by Vincent J. Viola and Douglas A. Cifu in 2008 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cifu Douglas AChief Executive OfficerFeb 07 '24Buy16.2150,000810,410584,132Feb 07 05:47 PM
Cifu Douglas AChief Executive OfficerSep 13 '23Buy17.0650,000853,150442,755Sep 13 04:39 PM
Molluso JosephCo-President & Co-COOSep 13 '23Buy17.1715,000257,481358,160Sep 13 04:40 PM
PBI - Pitney Bowes, Inc. - Stock Price Chart
TickerPBI [NYSE, RUT]
CompanyPitney Bowes, Inc.
CountryUSA
IndustryIntegrated Freight & Logistics
Market Cap1.02BEPS (ttm)-2.16
P/E-EPS this Y-162.50%
Forward P/E36.90EPS next Y720.00%
PEG-EPS past 5Y-
P/S0.31EPS next 5Y6.00%
P/B-EPS Q/Q63.21%
Dividend3.50%Sales Q/Q-0.48%
Insider Own13.11%Inst Own59.69%
Insider Trans0.00%Inst Trans-2.39%
Short Float8.19%EarningsMay 02/b
Analyst Recom3.00Target Price5.00
Avg Volume1.38M52W Range2.80 - 5.51
Pitney Bowes, Inc. is a global shipping and mailing company, which engages in the provision of technology, logistics, and financial services. It operates through the following segments: Global Ecommerce, Presort Services, and SendTech Solutions. The Global Ecommerce segment includes cross-border solutions, domestic parcel, and digital delivery services. The Presort Services segment involves the sortation services to qualify large volumes of first-class mail, marketing mail and bound and packet mail for postal work-sharing discounts. The SendTech Solutions segment consists of physical and digital mailing and shipping solutions, financing, services, supplies, and other applications. The company was founded by Arthur H. Pitney and Walter Bowes on April 23, 1920 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Everett Todd A.DirectorMay 03 '24Option Exercise0.0030,769041,241May 06 04:34 PM
Alberti-Perez MilenaDirectorMay 03 '24Option Exercise0.0030,769031,269May 06 04:34 PM
Brill StevenDirectorMay 03 '24Option Exercise0.0030,769034,494May 06 04:33 PM
Thomas James DarrellDirectorMay 03 '24Option Exercise0.0030,769034,494May 06 04:34 PM
May KatieDirectorMay 03 '24Option Exercise0.0030,769033,069May 06 04:34 PM
TWST - Twist Bioscience Corp - Stock Price Chart
TickerTWST [NASD, RUT]
CompanyTwist Bioscience Corp
CountryUSA
IndustryDiagnostics & Research
Market Cap2.80BEPS (ttm)-3.35
P/E-EPS this Y17.01%
Forward P/E-EPS next Y15.17%
PEG-EPS past 5Y-6.09%
P/S10.10EPS next 5Y-
P/B5.00EPS Q/Q24.44%
Dividend-Sales Q/Q25.13%
Insider Own4.34%Inst Own112.36%
Insider Trans-0.91%Inst Trans2.43%
Short Float21.42%EarningsMay 02/a
Analyst Recom1.80Target Price43.38
Avg Volume948.65K52W Range12.17 - 47.47
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leproust Emily M.Chief Executive OfficerMay 03 '24Sale37.134,163154,589509,986May 07 04:05 PM
Finn Patrick JohnPresident and COOMay 03 '24Sale37.132,31185,817173,895May 07 04:05 PM
Green PaulaSVP of Human ResourcesMay 03 '24Sale37.1391033,79291,511May 07 04:05 PM
Banyai WilliamSee RemarkMay 03 '24Sale37.1379829,633345,188May 07 04:05 PM
Cho DennisSee RemarksMay 03 '24Sale37.1356821,09280,436May 07 04:05 PM
EAT - Brinker International, Inc. - Stock Price Chart
TickerEAT [NYSE, RUT]
CompanyBrinker International, Inc.
CountryUSA
IndustryRestaurants
Market Cap2.78BEPS (ttm)3.37
P/E18.51EPS this Y38.51%
Forward P/E14.31EPS next Y11.19%
PEG0.96EPS past 5Y-3.47%
P/S0.65EPS next 5Y19.30%
P/B-EPS Q/Q-4.16%
Dividend-Sales Q/Q3.43%
Insider Own1.63%Inst Own103.60%
Insider Trans-11.60%Inst Trans0.37%
Short Float17.47%EarningsApr 30/b
Analyst Recom2.74Target Price54.40
Avg Volume1.32M52W Range28.23 - 60.97
Brinker International, Inc. engages in owning, developing, and franchising Chili's Grill and Bar and Maggiano's Little Italy restaurant brands. It operates through the Chili's and Maggiano's segments. The Chili's segment includes the results of company-owned Chili's restaurants in the U.S. and Canada as well as the results from its domestic and international franchise business. The Maggiano's segment refers to the results of company owned Maggiano's restaurants. The company was founded by Larry Lavine on March 13, 1975 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taylor Joseph GEVP & CFOMay 13 '24Option Exercise42.6140,0501,706,520106,336May 14 05:48 PM
Taylor Joseph GEVP & CFOMay 13 '24Sale60.4540,0502,421,02266,286May 14 05:48 PM
Taylor Joseph GEVP & CFOFeb 02 '24Option Exercise31.2214,538453,87680,824Feb 06 06:23 PM
Taylor Joseph GEVP & CFOFeb 02 '24Sale44.9724,1631,086,51456,661Feb 06 06:23 PM
Taylor Joseph GEVP & CFODec 12 '23Sale41.215,000206,05066,286Dec 13 04:24 PM
CRON - Cronos Group Inc - Stock Price Chart
TickerCRON [NASD]
CompanyCronos Group Inc
CountryCanada
IndustryDrug Manufacturers - Specialty & Generic
Market Cap1.12BEPS (ttm)-0.15
P/E-EPS this Y75.56%
Forward P/E-EPS next Y88.64%
PEG-EPS past 5Y-9.06%
P/S12.03EPS next 5Y45.80%
P/B1.04EPS Q/Q88.29%
Dividend-Sales Q/Q25.54%
Insider Own47.84%Inst Own12.08%
Insider Trans0.00%Inst Trans5.81%
Short Float3.02%EarningsMay 09/b
Analyst Recom2.38Target Price2.84
Avg Volume3.35M52W Range1.64 - 2.99
Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wagner AdamSVP, Head of Cronos IsraelMay 12 '24Option Exercise0.006,276027,999May 14 05:06 PM
Doucet Terrence Gregory JosephSee RemarksMay 12 '24Option Exercise0.0012,876044,202May 14 05:05 PM
Weigensberg AryeSee RemarksMay 12 '24Option Exercise0.009,014061,225May 14 05:09 PM
Wagner AdamSVP, Head of Cronos IsraelMay 10 '24Option Exercise0.0010,064021,723May 14 05:06 PM
Doucet Terrence Gregory JosephSee RemarksMay 10 '24Option Exercise0.001,560031,818May 14 05:05 PM
VTOL - Bristow Group Inc. - Stock Price Chart
TickerVTOL [NYSE, RUT]
CompanyBristow Group Inc.
CountryUSA
IndustryOil & Gas Equipment & Services
Market Cap1.02BEPS (ttm)0.04
P/E995.83EPS this Y99.63%
Forward P/E13.34EPS next Y36.38%
PEG142.26EPS past 5Y-
P/S0.76EPS next 5Y7.00%
P/B1.24EPS Q/Q515.26%
Dividend-Sales Q/Q11.61%
Insider Own3.18%Inst Own93.90%
Insider Trans-9.84%Inst Trans-1.55%
Short Float1.49%EarningsMay 07/a
Analyst Recom1.00Target Price42.00
Avg Volume118.03K52W Range21.85 - 34.73
Bristow Group, Inc. engages in the provision of aviation services to offshore energy companies and government entities. The company's services include personnel transportation, search and rescue (SAR), medevac, fixed wing transportation, unmanned systems, and ad-hoc helicopter services. It operates through the following segments: Offshore Energy Services, Government Services, Fixed Wing Services, and Other Services. Bristow Group was founded in 1955 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stepanek David F.Executive Vice President, CTOMar 19 '24Sale26.139,033236,04046,878Mar 20 08:08 PM
Brass Lorin L.DirectorMar 19 '24Sale25.657,500192,34626,388Mar 20 08:04 PM
Brass Lorin L.DirectorMar 18 '24Sale26.002005,20033,888Mar 20 08:04 PM
Solus Alternative Asset Manage10% OwnerDec 01 '23Sale26.0539,0471,017,1123,451,028Dec 01 05:57 PM
Solus Alternative Asset Manage10% OwnerNov 30 '23Sale25.9311,685303,0183,490,075Dec 01 05:57 PM
ATNM - Actinium Pharmaceuticals Inc - Stock Price Chart
TickerATNM [AMEX, RUT]
CompanyActinium Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap294.52MEPS (ttm)-1.72
P/E-EPS this Y6.65%
Forward P/E-EPS next Y65.56%
PEG-EPS past 5Y22.80%
P/S3681.55EPS next 5Y-
P/B6.63EPS Q/Q27.61%
Dividend-Sales Q/Q-
Insider Own3.88%Inst Own22.82%
Insider Trans0.00%Inst Trans6.71%
Short Float8.13%Earnings-
Analyst Recom1.00Target Price28.00
Avg Volume392.46K52W Range4.00 - 9.86
May-14-24Initiated Stephens Overweight $25
May-14-24 06:38PM Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial (PR Newswire) +11.63%
07:46AM Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target (MT Newswires)
May-13-24 08:30AM Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting (PR Newswire)
May-07-24 08:00AM Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern (PR Newswire)
Apr-18-24 08:00AM Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting (PR Newswire) -8.00%
Apr-15-24 12:54PM Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -6.22%
Apr-01-24 08:00AM Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting (PR Newswire) +9.32%
Mar-26-24 07:18AM Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy (PR Newswire) -6.34%
Mar-15-24 06:15AM High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment (InvestorPlace) +7.66%
Mar-11-24 07:30AM Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand (PR Newswire) -9.54%
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
12345671020